WO1996024350A1 - Pharmazeutische präparate zur tnf-inhibition - Google Patents
Pharmazeutische präparate zur tnf-inhibition Download PDFInfo
- Publication number
- WO1996024350A1 WO1996024350A1 PCT/DE1996/000257 DE9600257W WO9624350A1 WO 1996024350 A1 WO1996024350 A1 WO 1996024350A1 DE 9600257 W DE9600257 W DE 9600257W WO 9624350 A1 WO9624350 A1 WO 9624350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- formula
- alkyl
- treatment
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to the use of the compounds of the formula I for the production of medicaments for the treatment of diseases which are mediated by activation of the tumor necrosis factor (TNF).
- TNF tumor necrosis factor
- the compounds of formula I are described, for example, in USP-4,186,129 and WO 8602268. From these patents it is known that the compounds of the formula I have phosphodiesterase inhibitory activity and have central depressive, antidopaminergic, antinociceptive and anticonvulsive activity and are suitable for the local treatment of inflammation. It is also known from USP -4,824,838 that compounds of the formula I can be used as antidepressants.
- R ⁇ is hydrogen or C ⁇ .g-alkyl.
- the compounds of formula I can contain one or more chiral centers and also include the racemic diastereomeric mixtures and the individual optical isomers.
- Alkyl means in each case straight-chain or branched alkyl groups, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-methyl-butyl, 2,2-dimethylpropyl and hexyl .
- Alkyl residues with 1 to 4 carbon atoms are to be regarded as preferred.
- Alkenyl means for example 1-propenyl, 2-propenyl or 3-methyl-2-propenyl and alkynyl means for example propargyl.
- Cycloalkyl is understood to mean, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, in particular C3_5-cycloalkyls.
- Aryl or aralkyl each mean an aromatic ring or an aromatic ring system having 6 to 10 carbon atoms, such as, for example, phenyl, benzyl, phenethyl or naphthyl.
- a monocycle is to be regarded as preferred.
- Acyl is to be understood as meaning aliphatic and aromatic carboxylic acids, for example C 1-6 -alkanoyl, benzoyl.
- heterocycle encompasses a 5- or 6-membered saturated heterocycle having an oxygen, sulfur or nitrogen atom, for example 2- or 3-tetrahydropyranyl, 2- or 3-tetrahydrofuranyl, 2- or 3-tetrahydrothienyl, dihydropyranyl , Pyrrolidinyl, pvrrolinyl, piperidinyl and N-alkyl-pyrrolidinyl and N-alkyl-piperidinyl in which the alkyl radical contains 1-4 carbon atoms, preferably tetrahydrofuranyl.
- Halogen means chlorine, fluorine, bromine and iodine.
- Rl is methyl and R3 is hydrogen.
- R ⁇ is hydrogen
- R 2 is alkyl or cycloalkyl
- R 3 in the meaning CH 3 being preferred in particular.
- TNF Diseases that are mediated by TNF are understood to mean both diseases that are triggered by the production of TNF and diseases in which other cytokines such as 11-1 or 11-6 are influenced by TNF.
- TNF means both TNF- ⁇ and TNF- ⁇ , both of which are antagonized by the compounds of the formula I. TNF- ⁇ is preferably inhibited.
- the compounds of the formula I are therefore suitable for producing a pharmaceutical preparation which is used for the treatment and prophylaxis of diseases in living things which are triggered by stimulation of TNF.
- Diseases which are influenced by excessive or unregulated TNF stimulation are, for example, allergic and inflammatory diseases, autoimmune diseases, pulmonary diseases, infectious diseases and bone resorption diseases such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, sepsis, septic shock, endotoxin shock, Gram-negative sepsis, toxic shock syndrome, ARDS (acute respiratory distress syndrome), pulmonary sarcoidosis, asthma, silicosis, cachexia, ulcerative colitis, Crohn's disease, osteoporosis, organ damage after reperfusion, inflammatory diseases of the CNS such as cerebral infectious diseases, panalitis, multiple sclerosis, such as multiple sclerosis Mad cow disease, inflammatory skin diseases such as urticaria, psoriasis,
- the agents are produced by customary processes by bringing the active ingredient into the form of a pharmaceutical preparation with suitable carriers, auxiliaries and / or additives which is suitable for enteral or parenteral administration.
- the preparations thus obtained can be used as pharmaceuticals in human or veterinary medicine be used.
- the application can be administered orally or sublingually as a solid in the form of capsules or tablets or as a liquid in the form of solutions, suspensions, elixirs, aerosols or emulsions or rectally in the form of suppositories or in the form of injection solutions which can also be used subcutaneously, intramuscularly or intravenously, or topically or intrathecally.
- auxiliary organic and inorganic carrier materials are suitable as auxiliaries for the desired pharmaceutical formulation, such as, for. As water, gelatin, gum arabic, milk sugar, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. If necessary, preservatives, stabilizers, wetting agents, emulsifiers or salts for changing the osmotic pressure or buffer may also be included.
- the pharmaceutical preparations can be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for. B. present as solutions, suspensions or emulsions.
- Auxiliary materials such as salts, bile acids or animal or vegetable phospholipids and their mixtures as well as liposomes or their components can also be used as carrier systems.
- tablets, coated tablets or capsules with talc and / or hydrocarbon carrier or binder such as. B. lactose, corn or potato starch, suitable.
- the application can also be in liquid form, such as. B. as juice to which sweetener may be added.
- the compounds of formula I are used in doses sufficient to reduce TNF production to normal or lower levels.
- the dosage of the active ingredients can vary depending on the route of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors.
- the daily dose is 0.5-50 mg, preferably 0J- 5 mg, whereby the dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
- the activity of the compounds according to the invention can be demonstrated, for example, in animals suffering from experimental allergic encephalomyelitis (EAE), a CNS disease which is caused by T lymphocytes.
- EAE allergic encephalomyelitis
- the illness can be triggered on rodents and primates by immunization and histopathologically and symptomatically resembles the disease states in humans.
- the course of the disease can be followed using magnetic resonance imaging.
- Macrophages and microglial cells which have macrophage functions in the brain, mediate the release of TNF- ⁇ during experimental allergic encephalomyelitis (EAE). If macrophages are stimulated, for example by lipopolysaccharide (LPS), TNF- ⁇ is secreted in vitro and in vivo within hours.
- LPS lipopolysaccharide
- a urine macrophage Zeil line (RAW 264) was preincubated for 30 minutes in the presence and in the absence of various concentrations of PDE-IV inhibitors and then stimulated with LPS (10 ng / ml). The culture medium was removed 18 hours after stimulation and the TNF- ⁇ release was measured using a specific Elisa test.
- the test is available from various companies, including British Biotechnology, Genzyme, and is performed as described by the manufacturer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002212440A CA2212440C (en) | 1995-02-10 | 1996-02-09 | Pharmaceutical preparations for tnf inhibition |
EP96902870A EP0804192A1 (de) | 1995-02-10 | 1996-02-09 | Pharmazeutische präparate zur tnf-inhibition |
SK1073-97A SK283821B6 (sk) | 1995-02-10 | 1996-02-09 | Farmaceutické preparáty na inhibíciu tumornekrózafaktora |
MX9706086A MX9706086A (es) | 1995-02-10 | 1996-02-09 | Preparaciones farmaceuticas para inhibicion de tnf. |
AU47122/96A AU706159B2 (en) | 1995-02-10 | 1996-02-09 | Pharmaceutical preparations for TNF inhibition |
CZ19972513A CZ290671B6 (cs) | 1995-02-10 | 1996-02-09 | Farmaceutické preparáty pro inhibici tumornekrosefaktoru |
JP8523903A JPH11500110A (ja) | 1995-02-10 | 1996-02-09 | Tnf−抑制用製剤 |
FI973277A FI973277A (fi) | 1995-02-10 | 1997-08-08 | Farmaseuttisia valmisteita TNF:n estämiseksi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19505516.0 | 1995-02-10 | ||
DE19505516 | 1995-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996024350A1 true WO1996024350A1 (de) | 1996-08-15 |
Family
ID=7754327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1996/000257 WO1996024350A1 (de) | 1995-02-10 | 1996-02-09 | Pharmazeutische präparate zur tnf-inhibition |
Country Status (14)
Country | Link |
---|---|
US (1) | US6117895A (de) |
EP (1) | EP0804192A1 (de) |
JP (1) | JPH11500110A (de) |
KR (1) | KR19980702116A (de) |
CN (1) | CN1173818A (de) |
AU (1) | AU706159B2 (de) |
CZ (1) | CZ290671B6 (de) |
FI (1) | FI973277A (de) |
HU (1) | HUP9702408A3 (de) |
IL (1) | IL117090A (de) |
MX (1) | MX9706086A (de) |
SK (1) | SK283821B6 (de) |
WO (1) | WO1996024350A1 (de) |
ZA (1) | ZA961081B (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009965A2 (en) * | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
TW200732313A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2655369A1 (de) * | 1976-12-03 | 1978-06-08 | Schering Ag | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
DE2541855A1 (de) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
FR2358155A1 (fr) * | 1976-07-15 | 1978-02-10 | Lapinet Eugene | Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses |
US5783591A (en) * | 1984-10-19 | 1998-07-21 | Schering Aktiengesellschaft | Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation |
US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
DE3639225A1 (de) * | 1986-11-14 | 1988-05-19 | Schering Ag | Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka |
KR920702621A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
DE69128627T2 (de) * | 1990-08-03 | 1998-07-02 | Smithkline Beecham Corp | Tnf-inhibitoren |
PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
US5227369A (en) * | 1991-07-11 | 1993-07-13 | The Regents Of The University Of California | Compositions and methods for inhibiting leukocyte adhesion to cns myelin |
GB9204808D0 (en) * | 1992-03-04 | 1992-04-15 | Rhone Poulenc Rorer Ltd | Novel compositions of matter |
US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
-
1996
- 1996-02-09 JP JP8523903A patent/JPH11500110A/ja not_active Ceased
- 1996-02-09 HU HU9702408A patent/HUP9702408A3/hu unknown
- 1996-02-09 AU AU47122/96A patent/AU706159B2/en not_active Ceased
- 1996-02-09 MX MX9706086A patent/MX9706086A/es not_active IP Right Cessation
- 1996-02-09 IL IL11709096A patent/IL117090A/xx not_active IP Right Cessation
- 1996-02-09 SK SK1073-97A patent/SK283821B6/sk unknown
- 1996-02-09 WO PCT/DE1996/000257 patent/WO1996024350A1/de not_active Application Discontinuation
- 1996-02-09 ZA ZA961081A patent/ZA961081B/xx unknown
- 1996-02-09 CN CN96191868A patent/CN1173818A/zh active Pending
- 1996-02-09 EP EP96902870A patent/EP0804192A1/de not_active Withdrawn
- 1996-02-09 CZ CZ19972513A patent/CZ290671B6/cs not_active IP Right Cessation
- 1996-02-10 KR KR1019970705511A patent/KR19980702116A/ko not_active Application Discontinuation
- 1996-07-18 US US08/683,467 patent/US6117895A/en not_active Expired - Fee Related
-
1997
- 1997-08-08 FI FI973277A patent/FI973277A/fi not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2655369A1 (de) * | 1976-12-03 | 1978-06-08 | Schering Ag | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
Non-Patent Citations (1)
Title |
---|
R.SCHMIECHEN ET AL.: "Close coorelation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase", PSYCHOPHARMACOLOGY, vol. 102, no. 1, September 1990 (1990-09-01), pages 17 - 20, XP000568936 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009965A2 (en) * | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
WO1999009965A3 (en) * | 1997-08-21 | 1999-05-20 | Takeda Chemical Industries Ltd | Anti-inflammatory agent |
Also Published As
Publication number | Publication date |
---|---|
AU4712296A (en) | 1996-08-27 |
HUP9702408A2 (hu) | 1998-05-28 |
FI973277A0 (fi) | 1997-08-08 |
CZ290671B6 (cs) | 2002-09-11 |
EP0804192A1 (de) | 1997-11-05 |
IL117090A (en) | 2000-07-26 |
CZ251397A3 (en) | 1997-12-17 |
JPH11500110A (ja) | 1999-01-06 |
HUP9702408A3 (en) | 2000-08-28 |
SK107397A3 (en) | 1997-12-10 |
SK283821B6 (sk) | 2004-02-03 |
MX9706086A (es) | 1997-10-31 |
AU706159B2 (en) | 1999-06-10 |
FI973277A (fi) | 1997-08-08 |
ZA961081B (en) | 1996-10-15 |
US6117895A (en) | 2000-09-12 |
KR19980702116A (ko) | 1998-07-15 |
CN1173818A (zh) | 1998-02-18 |
IL117090A0 (en) | 1996-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60209504T2 (de) | Carbocyclische hydrazino-hemmer von kupferhaltigen aminoxidasen | |
DE69815090T2 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
Aoyama et al. | Neural networks applied to structure-activity relationships | |
DE69034223T2 (de) | Sertralin zur Behandlung der sozialen Phobie | |
DE60029634T2 (de) | Substituierte Piperazin-und Piperidin-Calciumkanalblocker | |
DE68901961T2 (de) | 3-(aminopropyl)methyl-phosphinsaeure als therapeutisches mittel. | |
EP0859766A1 (de) | Chirale methylphenyloxazolidinone | |
DE69022678T2 (de) | S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. | |
DE69017789T2 (de) | 1,2,3,4-Tetrahydro-9-Akridinaminderivate. | |
DE69825605T2 (de) | Behandlung der schizophrenie und der psychose | |
EP0038438A2 (de) | Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel | |
DE3855520T2 (de) | Methode zur Verbesserung des Schlafes | |
EP0804192A1 (de) | Pharmazeutische präparate zur tnf-inhibition | |
EP0003602B1 (de) | Pyrrolidin-Derivate zur Anwendung als therapeutische Wirkstoffe und diese enthaltende Arzneimittel | |
DE69003924T2 (de) | Verhinderung von Entzugserscheinungen. | |
DE60123528T2 (de) | Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit | |
EP0900212B1 (de) | Chirale phenyldihydrofuranone als pde-iv inhibitoren | |
DE69127285T2 (de) | Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen | |
DE69001526T2 (de) | Verwendung von Trifluormethylphenyltetrahydropyridinen zur Herstellung von Arzneimitteln zur Bekämpfung intestinaler Motilitätsstörungen. | |
DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
EP0270482B1 (de) | Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen | |
EP0821960A1 (de) | Verwendung von Xanthinderivaten zur Modulation der Apoptose | |
DE60300683T2 (de) | Prucaloprid-n-oxid | |
DE3906214A1 (de) | Verwendung von macrolactone als antiallergica | |
EP0524512A2 (de) | Antihypertensive Kombination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96191868.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN CZ FI HU JP KR MX SK |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996902870 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2212440 Country of ref document: CA Ref document number: 2212440 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 107397 Country of ref document: SK Ref document number: PV1997-2513 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 1996 523903 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 973277 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970705511 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1996902870 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-2513 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970705511 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970705511 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-2513 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996902870 Country of ref document: EP |